Study: Sildenafil for pulmonary hypertension in Neonates fou
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
A Study was conducted to provide an updated review and meta-analysis on the efficacy and safety of Sildenafil for treating persistent pulmonary hypertension in neonates (PPHN).

The principal outcomes include oxygenation parameters, hemodynamic metrics and echocardiographic measurements, as well as adverse outcomes.

Results:
--A total of 8 studies were included with 216 term and premature neonates with PPHN.

--Compelling evidence showed the use of sildenafil that could improve the prognosis of PPHN neonates, compared with baseline or placebo in neonates with PPHN, and a time-dependent pattern of the improvements can be observed.

--After 24 h of treatment, the Oxygenation index suggested a steady decrease (SD: 1.80) and sildenafil exerted peak effects after 72 h of treatment (SD: 4.02). No clinically significant side effects were identified.

--Egger's test and funnel plots of the major outcomes were performed, and the publication bias was not significant.

Finally, after using Sildenafil for PPHN in neonates, improvements in oxygenation index, pulmonary arterial pressure, and adverse outcomes were observed.

Source: https://onlinelibrary.wiley.com/doi/10.1002/ppul.25444?af=R
Like
Comment
Share